Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples